Table 2.

Therapeutic efficacies.

	mFOLFIRINOX (N = 27)	GOFL (N = 28)	Total (N = 55)
Best response to ICT
Partial response	6 (22.2%)	4 (14.3%)
Stable disease	20 (74.1%)	18 (64.3%)
Progressive disease	1 (3.7%)	6 (21.4%)
Disease control rate	26 (96.3%)	22 (78.6%)
Response after CCRT
Partial response	6	4
Stable disease	7	11
Progressive disease	8	2
Per-protocol R0/R1 resection	1 (3.7%)	5 (17.8%)	6 (10.9%)
Median (95% CI) PFS, months	6.6 (5.9–12.5)	7.6 (3.9–12.3)	6.7 (6.2–8.3)
9-month PFS rate	30.5%	35.9%	33.3%
Median (95% CI) OS, months	19.6 (13.4–22.9)	17.9 (13.4–23.9)	18.7 (15.8–21.9)
12-month OS rate (%)	88.9 (69.4–96.3)	82.1 (62.3–92.2)	85.5 (73.0–92.4)
24-month OS rate (%)	29.6 (14.1–47.0)	31.8 (15.7–49.1)	30.8 (19.2–43.1)